Data from preclinical studies suggest that inhibitors of the PI3K/Akt signaling pathway have been reported to be potent anti-angiogenic agents and contribute to the inhibition of tumor growth [37], [38], [39], [40], [41]. This evidence concerns the gene AKT1 and neoplasm.